Regeneron to Acquire 23andMe for $256 Million

Regeneron's acquisition of 23andMe marks a significant move in the biotechnology industry. The deal, valued at $256 million, comes as 23andMe navigates bankruptcy proceedings initiated in March. These proceedings raised concerns about data privacy, particularly following a 2023 data breach that exposed millions of customers' genetic information.

As part of the agreement, Regeneron commits to adhering to 23andMe's privacy policies and relevant laws. An independent Consumer Privacy Ombudsman will assess the transaction's impact on consumer privacy, providing a report to the U.S. Bankruptcy Court by June 10, 2025. Regeneron plans to utilize 23andMe's Personal Genome Service (PGS) and Total Health and Research Services, excluding Lemonaid Health, which will be wound down.

George D. Yancopoulos, M.D., Ph.D., of Regeneron, emphasized the company's commitment to safeguarding personal genetic data and improving individual health through genetic research. The acquisition aligns with Regeneron's history of translating DNA insights into innovative medicines.

Regeneron has committed to complying with 23andMe's privacy policies and applicable laws, ensuring data protection.

Yes, 23andMe will continue to operate as a wholly-owned unit of Regeneron.

The transaction is expected to close in the third quarter of 2025, pending court and regulatory approvals.

What are your thoughts on this acquisition? Do you think this will benefit genetic research and healthcare? Share this article with others who need to stay ahead of this trend!